Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Toward hepatitis C virus elimination using artificial intelligence

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2024;30(2):147-149. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0135

View: 942 Download: 42 Crossref: 1

Original Article

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang

Clin Mol Hepatol. 2019;25(4):400-407. Published online May 28, 2019

DOI: https://doi.org/10.3350/cmh.2019.0006

View: 6074 Download: 125 Web of Science: 9 Crossref: 7

Review

Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C

Seong Kyun Na, Byung-Cheol Song

Clin Mol Hepatol. 2019;25(3):234-244. Published online January 21, 2019

DOI: https://doi.org/10.3350/cmh.2018.0108

View: 8030 Download: 245 Web of Science: 21 Crossref: 23

Original Article

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience

Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim

Clin Mol Hepatol. 2017;23(4):323-330. Published online September 5, 2017

DOI: https://doi.org/10.3350/cmh.2017.0005

View: 7264 Download: 176 Web of Science: 6 Crossref: 9

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir

Han Na Choi, Jeong Eun Song, Hyeon Chul Lee, Hyeong Ho Jo, Chang Hyeong Lee, Byung Seok Kim

Clin Mol Hepatol. 2015;21(1):24-31. Published online March 25, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.1.24

View: 8654 Download: 109 Web of Science: 14 Crossref: 14

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

Byung Chul You, Young Seok Kim, Hun il Kim, Se Hun Kim, Seung Sik Park, Yu Ri Seo, Sang Gyune Kim, Se Whan Lee, Hong Soo Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim

Clin Mol Hepatol. 2012;18(3):272-278. Published online September 25, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.3.272

View: 7265 Download: 38 Crossref: 1

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B

Joon Chang Song, Bo Young Min, Jin-Wook Kim, Jong Yeop Kim, Yeo Myeong Kim, Cheol Min Shin, Sang Hyub Lee, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee

Clin Mol Hepatol. 2011;17(4):268-273. Published online December 26, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.4.268

View: 7400 Download: 63 Crossref: 8

The Korean Journal of Hepatology Elsewhere

Role of vitamin D in chronic hepatitis C

Tae Yeob Kim

Clin Mol Hepatol. 2011;17(2):170-172. Published online June 23, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.2.170

View: 5300 Download: 39

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin

Kyung-Ah Kim

Clin Mol Hepatol. 2011;17(1):84-86. Published online March 21, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.1.84

View: 5374 Download: 37 Crossref: 1

7

The Korean Joumal of Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response

In Hee Kim, M.D.

Clin Mol Hepatol. 2010;16(2):201-205. Published online June 25, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.2.201

View: 4415 Download: 14 Crossref: 1

3

Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b

Young-Joo Jin, M.D., Yoon Kyung Park, M.D., Gui Jun Yun, M.D. Han Chu Lee, M.D., Sook-Hyang Jeong, M.D. Gang Mo Kim, M.D., Young-Suk Lim, M.D., Young-Hwa Chung, M.D., Yung Sang Lee, M.D., Dong Jin Suh, M.D.

Clin Mol Hepatol. 2010;16(2):158-167. Published online June 25, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.2.158

View: 4176 Download: 22

Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response

Soung Won Jeong, M.D., Jin Dong Kim, M.D. Hyun Young Woo, M.D. Chan Ran You, M.D. Sung Won Lee, M.D. Myeong Jun Song, M.D. Jung Won Jang, M.D. Si Hyun Bae, M.D. Jong Young Choi, M.D. Seung Kew Yoon, M.D.

Clin Mol Hepatol. 2009;15(3):338-349. Published online September 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.3.338

View: 4615 Download: 24 Crossref: 11

Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection

Myoung Joo Kang, M.D., Eun Uk Jung, M.D., Sang Won Park, M.D., Paul Choi, M.D., Ji Hyun Kim, M.D., Sung Jae Park, M.D., Eun Taek Park, M.D., Youn Jae Lee, M.D., Sang Hyuk Lee, M.D., Sang Yong Seol, M.D.

Clin Mol Hepatol. 2008;14(3):318-330. Published online September 30, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.3.318

View: 5255 Download: 29 Crossref: 18

Hepatitis B core antigen expression pattern predicts response to Lamivudine therapy in patients with chronic hepatitis B

Kyeh Dong Shi, M.D., Seong Gyu Hwang, M.D., Ju Hyun Choi, M.D., Il Joon Hwang, M.D., Jai Ho Yoon, M.D., Kwang Il Kim, M.D. Chang-Il Kwon, M.D., Sung Pyo Hong, M.D., Pil Won Park, M.D., Kyu Sung Rim, M.D.

Clin Mol Hepatol. 2008;14(2):197-205. Published online June 20, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.2.197

View: 4485 Download: 24 Crossref: 3

Short-term Therapy with Pegylated Interferon plus Ribavirin for the Chronic Hepatitis C Genotype 2 Patients

Eun Uk Jung , Ji Hun Park , Kyung Im Pae , Suk Woo Kang , Sung Jae Park , Sam Ryong Jee , Eun Tak Park , Youn Jae Lee , Sang Hyuk Lee , Sang Young Seol

Clin Mol Hepatol. 2007;13(3):341-348. Published online September 20, 2007

DOI: https://doi.org/10.3350/kjhep.2007.13.3.341

View: 3905 Download: 21 Crossref: 2

1 |

Viewed By 5346	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5294	MAFLD: How is it different from NAFLD?
Viewed By 5192	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3886	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3840	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search